For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research ...

The intersection of sports marketing and the pharmaceutical industry offers a dynamic space where brands can leverage ...

Previously, she worked at Catamaran Bio, where she was also chief medical officer and, before that, she was senior vice ...

Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...